Debate

Low-dose stavudine trials: a public health priority for developing countries

W D Francois Venter, Steve Innes, Mark Cotton
Southern African Journal of HIV Medicine | Vol 13, No 1 | a154 | DOI: https://doi.org/10.4102/sajhivmed.v13i1.154 | © 2012 W D Francois Venter, Steve Innes, Mark Cotton | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 13 March 2012

About the author(s)

W D Francois Venter, Wits Reproductive Health and HIV Institute (WRHI), Department of Medicine, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
Steve Innes, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa
Mark Cotton, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa


Share this article

Bookmark and Share

Abstract

The debate around relooking at stavudine dosing, both in terms of the adult low-dose stavudine study and more broadly, is welcome. The study being proposed to evaluate low-dose stavudine v. tenofovir is a fairly standard placebo-controlled non-inferiority study. The study design is not controversial; however, the choice of study drug has attracted critical attention.

Keywords

No related keywords in the metadata.

Metrics

Total abstract views: 1258
Total article views: 2003

 

Crossref Citations

1. Antiretroviral dose reduction: good for patients and rollout
Jens D Lundgren, Andrew Phillips
The Lancet  vol: 383  issue: 9927  first page: 1442  year: 2014  
doi: 10.1016/S0140-6736(13)62556-8